

We are MeOmics

Our Neural Biomarker Platform Will
Transform Mental Healthcare

 Alasdair Pettigrew

 +44 7711 850102

 alasdair@meomics.tech

WWW.MEOMICS.TECH



— The Time is Right for the **MeOmics Vision**

There is no existing neuronal cell panel of mental health conditions...

Meaning no data available for AI-based med-tech companies to use, presenting early revenue opportunities for MeOmics

There is no high throughput platform for drug screening for mental health conditions...

Meaning drug developers need to reduce the cost and risk of clinical trials, presenting significant revenue opportunities for MeOmics

— Global Challenge of **Mental Healthcare**



Mental Health
Illnesses are:
**Half of Top 10
Conditions**



Global Mental
Healthcare Costs:
**Hundreds of
\$BILLIONS**






High Drug Dev.
Failure Rate:
**Only 1 in 20
Succeed**

— The MeOmics **Value Proposition**

A Neuronal Biomarker

Platform from clinical patients



MeOmics' Unique IP


Signal Data
+
Genomic Data
+
Clinical Data
+
AI/ML Analysis
=
Stratification of Patient Types

— The MeOmics **Product**

Population




“population on a plate”



+ Pharmacology




“drug” screen




= Prediction



AI/ML analysis to identify patient clusters and match drug to patient




— Highly Scalable **Business Models**





Revenue Growth Projections

MeOmics Revenue & Cost Plan



Competitive Landscape is Evolving



Global Research &
Press Interest e.g. :

The Economist



Early-Stage
Competitors are
Emerging e.g. :


Herophilus



Established Firms
May Pivot e.g. :

**Fujifilm Cellular
Dynamics**

— Significant Business **Validation & Traction**



— Recent **Value Inflection Points** for MeOmics

Recent Scientific & business Achievements (as of early 2024)



Pipeline from patients to iPSC

- ✓ Recruitment of 50 Schizophrenia Patients
- ✓ Generation of 300 iPSC lines (6 from each of the 50 donors)



Assay-ready cells

- ✓ Generation of iPSC master stocks from all 150 clones
- ✓ Stored as Neural Progenitor Cells, ready for cell assays



Parallelisation of MEA assays

- ✓ Ongoing assay of 28 patients and control iPSC-derived neurons (multi-well format)
- ✓ Testing 4 compounds from the Medicine Discovery Institute (MDI)



Differential Signals Detected and Patent(s) Being Filed

- ✓ Demonstrated electrophysiological signals differentiate patient & non-patient cells
- ✓ Indications of patient stratification differences - signal data AI/ML analysis commencing



Engagement with Initial Customers

- ✓ First commercial proposals submitted to rare disease patient groups
- ✓ Ongoing screening platform discussions with interested drug development companies

— MeOmics - Significant ESG Impact

MeOmics are committed
to protecting the
environment



Enabling the reduction
in animal testing in
drug development

MeOmics are committed
to good governance



Actively adopting best
practice governance
processes and policies

MeOmics will deliver
significant social
impact



Creating high-value
jobs and investment in
South Wales

The most **profound** MeOmics
social impact will be the global **transformation** of **mental healthcare**

— How MeOmics Will **Use** this **Pre-Seed Funding**



MeOmics
is now open to a

£1m Pre-Seed
Fundraise for 20% equity

SEIS/EIS Advanced
Assurance secured
from HMRC

WITH THIS MONEY WE WILL:

- + **Gather more patient samples** – targeting around 150 in total, gathering highly valuable data
- + **Accelerate** our **process throughput** with robotics and automation
- + Recruit **data analysts** to ramp up **AI data merging, ML** and **population modelling**
- + **Secure** early **revenues** from medical AI/ML companies
- + Commence preparations to establish our **lab in the Cardiff area**

This capital plus grant funding will provide a runway to the Seed fundraise of £3m in late 2025

Allowing the recruitment of a commercial team to find customers and grow revenues, carrying MeOmics past breakeven and into positive EBITDA

— Introducing Team MeOmics



Alasdair Pettigrew

Chief Executive Officer

Technology commercialisation – business start-up/spin-out expert

[Biography Link](#)



Dr Lucy Sykes

Special Advisor
(Chief Scientific Officer)

Expert in Cell & Molecular Biology

[Biography Link](#)



Professor
Adrian Harwood

Chief Technology Officer

Leading expert in neuronal cell biology and neuropsychopharmacology

[Biography Link](#)



Professor
Jeremy Hall

Chief Medical Officer

Leading expert in psychiatric phenotypes and biomarkers

[Biography Link](#)



Alicia Campbell

Stem Cell Biologist

Extensive experience in upscaling stem cells and process development

[Biography Link](#)



Professor
James Walters

Special Advisor

Expert in neuropsychiatric genetics and genomics

[Biography Link](#)

Supported by a distinguished Scientific Advisory Board

MeOmics plan to develop a unique platform for neural biomarker discovery that will transform mental healthcare

 Alasdair Pettigrew

 +44 7711 850102

 alasdair@meomics.tech

WWW.MEOMICS.TECH